
Glenmark Pharma hits 10% upper circuit, scales fresh 52-week high on $700 mn cancer drug deal
Glenmark Pharmaceuticals shares surged 10% to hit the upper circuit and a new 52-week high of Rs 2,095.65 on BSE on Friday, after its step-down, wholly owned subsidiary, Ichnos Glenmark Innovation (IGI), signed an exclusive global licensing agreement with …